EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy

Ashfaq Ur Rehman iD, Cizhang Zhao iD, Yongxian Wu, Qiang Zhu, Ray Luo iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25116201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Ashfaq Ur Rehman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Molecular Biology and Biochemistry, Chemical and Biomolecular Engineering, Materials Science and Engineering, and Biomedical Engineeri…. Hauptthemen laut MEDLINE: Neoplasms, Protein Tyrosine Phosphatase, Non-Receptor Type 11. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, NIH/NIGMS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SHP2, a pivotal component downstream of both receptor and non-receptor tyrosine kinases, has been underscored in the progression of various human cancers and neurodevelopmental disorders. Allosteric inhibitors have been proposed to regulate its autoinhibition. However, oncogenic mutations, such as E76K, convert SHP2 into its open state, wherein the catalytic cleft becomes fully exposed to its ligands. This study elucidates the dynamic properties of SHP2 structures across different states, with a focus on the effects of oncogenic mutation on two known binding sites of allosteric inhibitors. Through extensive modeling and simulations, we further identified an alternative allosteric binding pocket in solution structures. Additional analysis provides insights into the dynamics and stability of the potential site. In addition, multi-tier screening was deployed to identify potential binders targeting the potential site. Our efforts to identify a new allosteric site contribute to community-wide initiatives developing therapies using multiple allosteric inhibitors to target distinct pockets on SHP2, in the hope of potentially inhibiting or slowing tumor growth associated with SHP2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsProtein Tyrosine Phosphatase, Non-Receptor Type 11HumansAllosteric RegulationAllosteric SiteAntineoplastic AgentsBinding SitesMolecular Dynamics SimulationMutationProtein Binding

Stichwörter der Autor:innen

computational chemistrymolecular dynamicsmulti-scale dockingprotein tyrosine phosphatasestructure dynamics

Substanzen

Antineoplastic AgentsProtein Tyrosine Phosphatase, Non-Receptor Type 11PTPN11 protein, human

Autor:innen und Institutionen

  • Departments of Molecular Biology and Biochemistry, Chemical and Biomolecular Engineering, Materials Science and Engineering, and Biomedical Engineering, University of California, Irvine, CA 92697, USA.

ORCID-Profile: Ashfaq Ur Rehman, Cizhang Zhao, Ray Luo

Förderung

  • NIGMS NIH HHS
  • NIH HHS
  • NIH/NIGMS

Zitieren

APA

Rehman, A. U., Zhao, C., Wu, Y., Zhu, Q., & Luo, R. (2024). Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25116201

Vancouver

Rehman AU, Zhao C, Wu Y, Zhu Q, Luo R. Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25116201

BibTeX
@article{Rehman2024,
  author = {Rehman, Ashfaq Ur and Zhao, Cizhang and Wu, Yongxian and Zhu, Qiang and Luo, Ray},
  title = {Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25116201}
}
Kostenlos starten →